Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes

American Journal of Nephrology

Volumn 30, Issue 6, 2009, Pages 481-490

  Seo, Ji Yeon ^a,c   Park, Jehyun ^b,c   Yu, Mi Ra ^b   Kim, Yu Seun ^c   Ha, Hunjoo ^a   Lee, Hi Bahl ^b  

^a Ewha Womans University   (South Korea)

^b Soon Chun Hyang University

^c Yonsei University College of Medicine   (South Korea)

Author keywords

ig h3; Diabetic nephropathy; Knockout mice; Matrix metalloproteinase; Mesangial cells; Plasmin; Plasminogen activator inhibitor 1; Renal fibrosis; Transforming growth factor 1

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GLUCOSE BLOOD LEVEL; KIDNEY CORTEX; KIDNEY FIBROSIS; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; CELL LINE, TRANSFORMED; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FEEDBACK, PHYSIOLOGICAL; FIBRINOLYSIN; FIBRONECTINS; FIBROSIS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MESANGIAL CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSMOTIC PRESSURE; PROMOTER REGIONS, GENETIC; PROTEINURIA; RNA, MESSENGER; SERPINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70349409438     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000242477     Document Type: Article

References (40)

1. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984; 74: 1143-1155.
2. Bilos R: Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med 2008; 25(suppl 2):25-29.
3. Ingelfinger JR: Forestalling fibrosis. N Engl J Med 2003; 349: 2265-2266.
4. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000; 58: 1841-1850.
5. Eddy AA: Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283:F209-F220.
6. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/ MMP-2 cascade. Kidney Int 1995; 47: 1039-1047.
7. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP: Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin- 1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13076.
8. Monea S, Lehti K, Keski-Oja J, Mignatti P: Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002; 192: 160-170.
9. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB: Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 1997; 51: 1376-1382.
10. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez- Guisa JM, Degen JL, Shvil Y, Eddy AA: Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007; 18: 846-859.
11. Eddy AA, Fogo AB: Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
12. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB: Reactive oxygen species mediates HG-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kindey Int 2005; 67: 1762-1771.
13. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, Tipping PG: Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997; 185: 963-968.
14. Kitching AR, Kong YZ, Huang XR, Davenport P, Edgtton KL, Carmeliet P, Holdsworth SR, Tipping PG: Plasminogen activator inhibitor- 1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14: 1487-1495.
15. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA: PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 2001; 60: 587-596.
16. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA: A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003; 112: 379-388.
17. Krag S, Danielsen CC, Carmeliet P, Nyengaard J, Wogensen L: Plasminogen activator inhibitor-1 gene deficiency attenuates TGFbeta1- induced kidney disease. Kidney Int 2005; 68: 2651-2666.
18. Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA: Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpression mice. Kidney Int 2005; 67: 2221-2238.
19. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, Hsueh WA: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 2005; 67: 1297-1307.
20. Collins SJ, Alexander SL, López-Guisa JM, Cai X, Maruvada R, Chua SC, Zhang G, Okamura DM, Matsuo S, Eddy AA: Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 2006; 104:e23-e34.
21. Lassila M, Fukami K, Jandeleit-Dahm K, Semple T, Carmeliet P, Cooper ME, Kitching AR: Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia 2007; 50: 1315-1326.
22. Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA: A PAI-1 mutant, PAI- 1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 2008; 19: 329-338.
23. Ha H, Oh E, Lee HB: The role of plasminogen activator inhibitor1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009; 5: 203-211.
24. Gilbert RE, Wilkinson-Berka JL, Johnson DW, Cox A, Soulis T, Wu LL, Kelly DJ, Jerums G, Pollock CA, Cooper ME: Renal expression of TGF-β inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Kidney Int 1998; 54: 1052-1062.
25. Jiang Z, Seo JY, Ha H, Lee EA, Kim YS, Han DC, Uh ST, Park CS, Lee HB: Reactive oxygen species mediate TGF-β1-induced plasminogen activator inhibtor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 2003; 309: 961-966.
26. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK: IN-1130, a novel transforming growth factor-β type1 receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006; 70: 1234-1243.
27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 1976; 72: 248-254.
28. Noh H, Kim JS, Han K-H, Lee GT, Song JS, Chung SH, Jeon JS, Ha H, Lee HB: Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006; 69: 2022-2028.
29. Kim SJ, Glick A, Sporn MB, Roberts AB: Characterization of the promoter region of the human transforming growth factor-beta 1 gene. J Biol Chem 1989; 264: 402-408.
30. Kim SJ, Jeang KT, Glick AB, Sporn MB, Roberts AB: Promoter sequences of the human transforming growth factor-beta 1 gene responsive to transforming growth factor-beta 1 autoinduction. J Biol Chem 1989; 264: 7041-7045.
31. Lee HB, Yu MR, Song JS, Ha H: Reactive oxygen species amplify protein kinase C signaling in HG-induced fibronectin expression by peritoneal mesothelial cells. Kidney Int 2004; 65: 1170-1179.
32. Okada Y, Morodomi T, Enghild JJ, Suzuki K, Yasui A, Nakanishi I, Salvesen G, Nagase H: Matrix metalloproteinase 2 from human rheumatoid fibroblasts. Purification and activation of the precursor and enzymatic properties. Eur J Biochem 1990; 194: 721-730.
33. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981; 41: 4629-4636. (Pubitemid 12201384)
34. Lee HB, Seo J, Jiang Z, Ha H: Suppression of plasminogen activator inhibitor-1 inhibits HG- and TGF-β1-induced fibronectin secretion and increases MMP2 activity by mesangial cells (abstract). J Am Soc Nephrol 2002; 13: 169A.
35. Baricos WH, Cortez SL, Deboisblanc M, Xin S: Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999; 10: 790-795.
36. Mclennan SV, Fisher E, Martell SY, Death AK, Williams PF, Lyons JG, Yue DK: Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl 2000; 77:S81-S87.
37. Baricos WH, Reed JC, Cortez SL: Extracellular matrix degradation by cultured mesangial cells: mediators and modulators. Exp Biol Med (Maywood) 2003; 228: 1018-1022.
38. Wong AP, Cortez SL, Baricos WH: Role of plasmin and gelatinase in extracellular matrix degradation by cultured rat mesangial cells. Am J Physiol 1992; 263:F1112-F1118.
39. Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, Carmeliet P, Rondeau E: Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor β. FASEB J 2003; 17: 1904-1906.
40. Pedroja BS, Kang LE, Imas AO, Carmeliet P, Bernstein AM: Plasminogen activator inhibitor- 1 regulates integrin αvβ 3 expression and autocrine TGFβ signaling. J Biol Chem 2009; 284: 20708-20717.